



**Kadimastem is a Clinical Stage Company Developing
Regenerative Therapies for Therapeutic Needs**

(TASE: KDST)

Company's Profile

A clinical stage biotechnology company that develops regenerative therapies based on stem cells

Kadimastem was established in 2009 and is Traded on TASE since 2013 (TASE: KDST ,)



Two lead programs in:

- Amyotrophic Lateral Sclerosis (ALS)- AstroRx®
- Diabetes- ILCsRx

In march 2018 the company received an approval from the Israeli Ministry of health to commence a first-in-human phase I/IIa clinical trial with AstroRx® in ALS patients. Patient enrolment will begin in Q2/2018



Infrastructure:

- 31 employees (9 PhDs)
- State-of-the-Art laboratories including a cGMP manufacturing facility



Strong IP

4 extensive patent families

Experienced Management

Yossi Ben Yossef

CEO and Co-Founder


- Over 15 years of experience in leading investments and building start-up companies in the field of life sciences
- Investment and active involvement in Evogene, VBL, Radvision, Rosetta Genomics, BiondVax, Comfi, Wizcom

Professor Michel Revel

Chief Scientist and Co-Founder

- Professor Emeritus of molecular genetics at the Weizmann Institute of Science
- Israel Prize laureate
- Over 30 years of experience in development and global commercialization of advanced biotechnological products
- Developed Merck's blockbuster drug REBIF® for multiple sclerosis (\$1.8B USD in sales in 2016)

Company Products/Pipeline



AstroRx®

- Clinical grade human astrocytes (the nervous system supporting cells) for the treatment of ALS and other neurodegenerative diseases
- Received approval by the Israeli Ministry of Health to commence our phase I/IIa clinical trial in ALS patients.
- Patient enrollment in Q2/2018



ILCsRx

- Clinical-grade pancreatic islet-like cells, producing insulin and other hormones that normalize blood glucose, for use as encapsulated implants in the treatment of Diabetes. The encapsulation envelop/device should prevent rejection by the immune system of the host, enable survival and full physiological functionality of the encapsulated cells. It should also prevent the cells from immigrating in the host body and permit easy retrieval of the transplanted cells

Kadimastem's goals in consortium activities

1. 3D printing of cell encapsulating devices
2. 3D printing of cell-containing organoids/organs
3. Improved survival and functionality of cells within device and while being printed

Kadimastem's expectations from consortium members

1. 3D printers and scaffolds for cell encapsulating devices
2. 3D printers and "inks" for cell-containing organoids/organs
3. 3D printer's "ink"/scaffolds in which cells can survive while being printed

Thank You



www.kadimastem.com



info@kadimastem.com



073-7971601